Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|11|3|338-346

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.3, 2011-03, pp. : 338-346

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome

By  

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 332-337

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition

By  

Current Pharmaceutical Design, Vol. 19, Iss. 22, 2013-01 ,pp. : 4053-4093

Bentham Science Publishers

Access to resources Recommend Favorite

Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies

By  

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 21, 2011-11 ,pp. : 2623-2631

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the ubiquitin-proteasome system for cancer therapy

By Shen Min  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 9, 2013-09 ,pp. : 1091-1108

Informa Healthcare

Access to resources Recommend Favorite

Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 10, Iss. 3, 2010-06 ,pp. : 158-164

Bentham Science Publishers

Access to resources Recommend Favorite